Hodgkin Lymphoma

Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma
May 14, 2019
ByAvyakta Kallam, MD|Julie M. Vose, MD, MBA

In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.

Adding the T-Cell Booster Decitabine to Anti–PD-1 Therapy in Hodgkin Lymphoma
May 03, 2019
ByLeah Lawrence

Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.

Risk of Future Cancers in Survivors of Childhood Hodgkin Lymphoma
January 16, 2019
ByJohn Schieszer

Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.